Go Set a Watchman?

[1]  J. Odell,et al.  Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. , 1996, The Annals of thoracic surgery.

[2]  M. Chung,et al.  Cardioversion Guided by Transesophageal Echocardiography: The ACUTE Pilot Study: A Randomized, Controlled Trial , 1997, Annals of Internal Medicine.

[3]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[4]  Andrea Natale,et al.  Percutaneous Closure of the Left Atrial Appendage. , 2012, Cardiac electrophysiology clinics.

[5]  M. Price,et al.  Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. , 2015, JACC. Cardiovascular interventions.

[6]  Saibal Kar,et al.  Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. , 2015, Journal of the American College of Cardiology.

[7]  R. Wilensky,et al.  Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. , 2015, JAMA internal medicine.

[8]  H. Calkins,et al.  2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. , 2015, Journal of the American College of Cardiology.

[9]  Jonathan W. Waks,et al.  Left Atrial Appendage Closure to Reduce the Risk of Thromboembolic Complications in Atrial Fibrillation: Pay Now and Possibly Pay Later? , 2015, Journal of the American College of Cardiology.

[10]  A. Hobbs,et al.  Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial. , 2016, International journal of cardiology.